Formalin-fixed, paraffin-embeddedhuman tonsil stained with Biotin-conjugated CD73Mouse Monoclonal Antibody (NT5E/2646).
Formalin-fixed, paraffin-embedded human tonsil stained with Biotin-conjugated CD73 Mouse Monoclonal Antibody (NT5E/2646).
SDS-PAGE Analysis Purified CD73 Mouse Monoclonal Antibody (NT5E/2646) (unconjugated). Confirmation of Integrity and Purity of Antibody.
Analysis of Protein Array containing more than 19,000 full-length human proteins using CD73 Mouse Monoclonal Antibody (CD73/2646)
Known Applications & Suggested Dilutions
Host / Ig Isotype
Mol. Weight of Antigen
Specificity & Comments
CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies.